Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 13
Submit an article Journal homepage
155
Views
0
CrossRef citations to date
0
Altmetric
Articles

Successful and safe response to ibrutinib alone in treating relapsed Waldenström macrogobulinemia and related acquired von Willebrand syndrome: an option to consider

Alexandre Buteleta Hemostasis and transfusion department, Biology Pathology Center, University hospital of Lille, Lille, FranceORCID Iconhttps://orcid.org/0000-0002-3708-8769
ORCID Icon,
Stéphanie Poulainb Laboratory of Hematology, Biology Pathology Center, CHU of Lille, INSERM UMR-S 1177, Team 4, Cancer Research Institute, Univ. Lille, FranceORCID Iconhttps://orcid.org/0000-0002-1792-7270
ORCID Icon,
Emmanuelle Jeanpierrea Hemostasis and transfusion department, Biology Pathology Center, University hospital of Lille, Lille, FranceORCID Iconhttps://orcid.org/0000-0002-7900-0518
ORCID Icon,
Micha Srourc Service des Maladies du Sang, Centre Hospitalier Universitaire de Lille, Lille, FranceORCID Iconhttps://orcid.org/0000-0002-8519-4187
ORCID Icon,
Morgane Nudelc Service des Maladies du Sang, Centre Hospitalier Universitaire de Lille, Lille, FranceORCID Iconhttps://orcid.org/0000-0001-9100-2316
ORCID Icon,
Paul Chauvetc Service des Maladies du Sang, Centre Hospitalier Universitaire de Lille, Lille, FranceORCID Iconhttps://orcid.org/0000-0001-6326-9283
ORCID Icon,
Anne Bautersa Hemostasis and transfusion department, Biology Pathology Center, University hospital of Lille, Lille, FranceORCID Iconhttps://orcid.org/0000-0003-2734-456X
ORCID Icon,
Sophie Susena Hemostasis and transfusion department, Biology Pathology Center, University hospital of Lille, Lille, FranceORCID Iconhttps://orcid.org/0000-0001-5953-163X
ORCID Icon,
Annabelle Duponta Hemostasis and transfusion department, Biology Pathology Center, University hospital of Lille, Lille, FranceORCID Iconhttps://orcid.org/0000-0002-1554-9931
ORCID Icon &
Marie de Charettec Service des Maladies du Sang, Centre Hospitalier Universitaire de Lille, Lille, France;d Service d’hématologie, Centre Hospitalier Universitaire de la Réunion, Saint Denis, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3108-0691
ORCID Icon show all
Pages 3100-3104 | Received 07 Jul 2022, Accepted 31 Jul 2022, Published online: 13 Sep 2022

References

  • Dimopoulos MA, Kastritis E. How I treat waldenström macroglobulinemia. Blood. 2019;134(23):2022–2035.
  • Hivert B, Caron C, Petit S, et al. Clinical and prognostic implications of low or high level of von willebrand factor in patients with waldenström macroglobulinemia. Blood. 2012;120(16):3214–3221.
  • Tiede A, Rand JH, Budde U, et al. How I treat the acquired von willebrand syndrome. Blood. 2011;117(25):6777–6785.
  • Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth international workshop for waldenström macroglobulinaemia. Lancet Haematol. 2020;7(11):e827–e837.
  • Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von willebrand factor-dependent platelet functions. Blood. 2014;124(26):3991–3995.
  • Poulain S, Roumier C, Bertrand E, et al. TP53 mutation and its prognostic significance in waldenstrom’s macroglobulinemia. Clin Cancer Res. 2017;23(20):6325–6335.
  • Owen RG, Kyle RA, Stone MJ, VIth International Workshop on Waldenström macroglobulinaemia, et al. Response assessment in waldenström macroglobulinaemia: update from the VIth international workshop. Br J Haematol. 2013;160(2):171–176.
  • O'Sullivan JM, Ward S, Lavin M, et al. Von willebrand factor clearance - biological mechanisms and clinical significance. Br J Haematol. 2018;183(2):185–195.
  • Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015;29(4):783–787.
  • Castillo JJ, Gustine JN, Meid K, et al. Low levels of von willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with waldenström macroglobulinaemia. Br J Haematol. 2019;184(6):1011–1014.
  • Poza M, Íñiguez R, Zamanillo I, et al. Ibrutinib effect in acquired von willebrand syndrome secondary to waldenström macroglobulinemia. Ther Adv Hematol. 2021;12:204062072110393.
  • Kong D, Li Y, Fu C, et al. Bortezomib provides favorable efficacy in type 3 acquired von willebrand syndrome related to lymphoplasmacytic lymphoma/waldenstrom’s macroglobulinemia. Leuk Lymphoma. 2022;63(2):491–494.
  • Bye AP, Unsworth AJ, Desborough MJ, et al. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Adv. 2017;1(26):2610–2623.
  • Series J, Garcia C, Levade M, et al. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions. Haematologica. 2019;104(11):2292–2299.
  • Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038–2050.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.